Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tizanidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 14/20 | 1.00 |
| ▸ | ADRA2B known ✓ | P18089 | 12/20 | 1.00 |
| ▸ | ADRA2C known ✓ | P18825 | 12/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 7/20 | 0.58 |
| ▸ | ADRA1B | P35368 | 7/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.58 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tizanidine SCHEMBL20769844 | 1.00 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL6472652 | 0.99 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL41199 | 0.99 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2469048 | 0.97 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2471445 | 0.93 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL28207600 | 0.93 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL4725711 | 0.93 | ADRA2A (0.86) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL28345161 | 0.92 | ADRA2A (0.84) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL2469648 | 0.92 | ADRA2A (0.84) | ADRA2AADRA2BADRA2CADRA1ALMNA | |
| Tizanidine SCHEMBL4333463 | 0.91 | ADRA2A (0.82) | ADRA2AADRA2BADRA2CADRA1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13799 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| US-12588828-B2 | Methods and systems for diagnosing and treating fibromyalgia | KATZ ROBERT S (US) | 2026-03-31 | — | — | US | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260028460-A1 | Erodible Film and Method of Making | VIPA PHARMA INC (US) | 2026-01-29 | — | — | US | claimed |
| EP-4683627-A1 | AMELIORATION OF DRUG-DRUG INTERACTIONS | Ontrack Therapeutics Limited (GB) | 2026-01-28 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-0242827-B1 | SURFACE SHAPED THERAPEUTIC SYSTEM, METHOD FOR ITS MANUFACTURE, AND ITS APPLICATION | Lohmann GmbH & Co. KG (DE) | 1991-12-27 | — | — | EP | claimed |
| WO-1989011851-A1 | TREATMENT OF INFLAMMATORY DISEASES, IN PARTICULAR RHEUMATOID ARTHRITIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1989-12-14 | — | — | WO | claimed |
| EP-0315219-A2 | Pharmaceutical compositions | SANDOZ AG (CH) | 1989-05-10 | — | — | EP | claimed |
| EP-0170193-A2 | Feedstuff additive for the growth promoting of agricultural useful animals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 1986-02-05 | — | — | EP | claimed |
| EP-0155229-A2 | Pharmaceutical compositions | SANDOZ AG (CH) | 1985-09-18 | — | — | EP | claimed |
| WO-1985003878-A1 | PHARMACEUTICAL COMPOSITIONS | SANDOZ AG (CH) | 1985-09-12 | — | — | WO | claimed |
| US-4515802-A | ACETAMINOPHEN AND TIZANIDINE | SANDOZ LTD. (CH) | 1985-05-07 | — | — | US | claimed |
| US-4442084-A | ABSORPTION, LIQUID PHASE CLAUS PROCESS, RECYCLING | SANDOZ LTD. (CH) | 1984-04-10 | — | — | US | claimed |
| US-4333945-A | Thiazoline and imidazoline derivatives useful as minor tranquilizers | SANDOZ LTD. (CH) | 1982-06-08 | — | — | US | claimed |
| US-4329354-A | HAVING A 2,1,3-BENZOTHIADIAZOLE COMPONENT | SANDOZ LTD. (CH) | 1982-05-11 | — | — | US | claimed |